← Back to Search

Behavioural Intervention

Diabetes BOOST Program for Type 2 Diabetes

N/A

Waitlist Available

Led By Daniel J Amante, PhD, MPH

Research Sponsored by Daniel Amante

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age > 18 years

Diagnosis of type 2 diabetes

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 - 6 months

Awards & highlights

Study Summary

This trial aims to develop a culturally-appropriate diabetes self-management program for Latinx patients, tested in collaboration with clinical, community and patient partners.

Who is the study for?

This trial is for Hispanic/Latinx adults over 18 with type 2 diabetes who prefer to speak Spanish and have completed a diabetes self-management training in the past year. It's not suitable for those with cognitive impairments, pregnant women, or current prisoners.Check my eligibility

What is being tested?

The study is testing 'DM-BOOST para Latinx,' an adapted version of the DM-BOOST program designed to help Latinx patients manage their diabetes using behavioral economics and technology. The effectiveness will be assessed through community-based participatory research.See study design

What are the potential side effects?

Since this intervention involves educational and support programs rather than medications, traditional side effects are not expected. However, participants may experience stress or discomfort related to lifestyle changes encouraged by the program.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am older than 18 years.

Select...

I have been diagnosed with type 2 diabetes.

Select...

I completed a diabetes self-management training last year.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 - 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 - 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 - 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Process Evaluation

Secondary outcome measures

Change in HbA1c Percentage

Diabetes self-efficacy

Diabetes self-management skills

+1 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention - Diabetes BOOSTExperimental Treatment1 Intervention

Intervention group participants will complete a baseline survey, receive a referral to DSMT from the research team, a mailed welcome letter and self-care education sent via a series of personalized patient portal secure messages, text messages, and video call. They will be sent text messages with information about one of the American Association of Diabetes Educators 7 self-care behaviors and will receive encouragement to author their own self-management behavioral goals. Participants will also complete a telehealth training video call with research staff to review the functionality of their patient portal and refine diabetes-related goals. The participant will then be encouraged to send a patient portal message to their DSMT CDCES that includes their personalized goals prior to their scheduled DSMT session. They will then complete a 3-month follow-up survey and qualitative interview.

Group II: Usual CareActive Control1 Intervention

Comparison Group participants will complete a baseline survey, receive a DSMT referral request from research team to their primary care provider and a mailed welcome letter. The mailed letter will welcome the participant to the study and contain general information about diabetes self-care behaviors and goal setting. They will complete a DSMT session. They will then complete a 3-month follow-up survey and qualitative interview.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Diabetes BOOST

2021

N/A

~70

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Daniel AmanteLead Sponsor

1 Previous Clinical Trials

66 Total Patients Enrolled

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH

2,356 Previous Clinical Trials

4,314,996 Total Patients Enrolled

Daniel J Amante, PhD, MPHPrincipal InvestigatorUMass Chan Medical School

1 Previous Clinical Trials

66 Total Patients Enrolled

Media Library

Diabetes BOOST (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05583877 — N/A

Type 2 Diabetes Research Study Groups: Intervention - Diabetes BOOST, Usual Care

Type 2 Diabetes Clinical Trial 2023: Diabetes BOOST Highlights & Side Effects. Trial Name: NCT05583877 — N/A

Diabetes BOOST (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05583877 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available positions in this research project for participants?

"According to clinicaltrials.gov, this particular medical trial is no longer actively recruiting patients; the initial listing was posted on December 1st 2022 and last updated on October 19th 2022. Despite the conclusion of recruitment for this study, there are over 1391 other trials currently seeking participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

DM-BOOST Para Latinx: a Diabetes Mellitus Program Using Behavioral Economics to Optimize Outreach and Self-management Support With Technology for Latinx Patients

Daniel Amante 2024. "DM-BOOST Para Latinx: a Diabetes Mellitus Program Using Behavioral Economics to Optimize Outreach and Self-management Support With Technology for Latinx Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05583877.